Background Obstructive sleep apnoea (OSA) is a common chronic respiratory disease
associated with a high burden of disabilities related to sleepiness and reduced quality of life …

Obstructive sleep apnea (OSA) is associated with excessive daytime sleepiness (EDS).
Pharmacotherapy offers a potential treatment approach for EDS in OSA patients. This …

Obstructive sleep apnea (OSA) is a common disorder. Its prevalence is increasing
worldwide, partially due to increasing rates of obesity, and OSA has a well-documented …

While the significance of obtaining restful sleep at night and maintaining daytime alertness is
well recognized for human performance and overall well-being, substantial variations exist …

Abstract Objective/Background The aim of this study was to compare the efficacy of
orthognathic surgery combined with soft tissue surgery with that of soft tissue surgery alone …

There remains an unmet need for a targeted treatment to address residual excessive
daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA) after primary …

Solriamfetol (SUNOSI®) is an oral selective dopamine and norepinephrine reuptake
inhibitor approved in the EU and the USA for improving wakefulness in adults with excessive …

Objective To develop a robust machine learning prediction model for the automatic
screening and diagnosis of obstructive sleep apnea (OSA) using five advanced algorithms …

Introduction Obstructive sleep apnea (OSA) is a chronic condition characterized by
intermittent hypoxia (IH) and sleep fragmentation (SF). OSA can induce excessive daytime …

Background Internationally accepted standards for systematic reviews necessitate
assessment of the risk of bias of primary studies. Assessing risk of bias, however, can be …